Literature DB >> 20206875

The prothrombotic potential of platelet factor 4.

Jecko Thachil1.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder initiated by heparin administration. It is caused by the formation of pathogenic antibodies to complexes of platelet factor-4 (PF4) and heparin on platelet surfaces that cause platelet activation, aggregation and thrombosis. There has been intense research on this intriguing, drug-related thrombocytopenia explaining several characteristic aspects of this condition. However, prothrombotic potential of the key player, PF4 has not been investigated in many studies although it has been shown to be critical in monocyte chemotaxis, monocyte-platelet interaction, and megakaryocyte suppression, all of which can contribute to the pathophysiology of HIT. This article explains the important role of PF4 released during platelet activation with the administration of heparin in the pathogenesis of thrombocytopenia and thrombosis in HIT. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20206875     DOI: 10.1016/j.ejim.2009.11.007

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  6 in total

1.  Argatroban in heparin-induced thrombocytopenia: rationale for use and place in therapy.

Authors:  Ramandeep K Bambrah; Dat C Pham; Fauzia Rana
Journal:  Ther Adv Chronic Dis       Date:  2013-11       Impact factor: 5.091

Review 2.  Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data.

Authors:  Gaurav Sharma; Jeffrey S Berger
Journal:  J Thromb Thrombolysis       Date:  2011-08       Impact factor: 2.300

3.  Platelet factor 4 protects bone marrow mesenchymal stem cells from acute radiation injury.

Authors:  J-J Chen; Y Gao; Q Tian; Y-M Liang; L Yang
Journal:  Br J Radiol       Date:  2014-06-12       Impact factor: 3.039

4.  Low levels of circulating platelet factor 4 (PF4, CXCL4) in subclinically hypothyroid autoimmune thyroiditis.

Authors:  S Görar; E Ademoğlu; A Çarlıoğlu; B Alioğlu; H Bekdemir; B Sağlam; Z Candan; R Üçler; C Culha; Y Aral
Journal:  J Endocrinol Invest       Date:  2015-07-05       Impact factor: 4.256

Review 5.  Multifaceted prospects of nanocomposites for cardiovascular grafts and stents.

Authors:  Muthu Vignesh Vellayappan; Arunpandian Balaji; Aruna Priyadarshini Subramanian; Agnes Aruna John; Saravana Kumar Jaganathan; Selvakumar Murugesan; Eko Supriyanto; Mustafa Yusof
Journal:  Int J Nanomedicine       Date:  2015-04-07

6.  Effects of ulinastatin on coagulation in high-risk patients undergoing off-pump coronary artery bypass graft surgery.

Authors:  Na-Young Kim; Jae-Kwang Shim; Seo-Ouk Bang; Jee-Suk Sim; Jong-Wook Song; Young-Lan Kwak
Journal:  Korean J Anesthesiol       Date:  2013-02-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.